A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France
This study focuses on people in France who have developed a widespread Borrelia infection, sometimes known as Lyme disease, after receiving a specific type of medication called anti-CD20 antibodies. These medications are used for various conditions, including some cancers and autoimmune diseases. Researchers want to gather detailed information about these cases, including their symptoms, lab test results, imaging, and how their medication might be involved. The main goal is to understand more about how these infections develop in people on anti-CD20 treatments. This information could help doctors better recognise, treat, and manage Borrelia infections in similar patients in the future.
At a glance
What is this study about?
This study is gathering information about people in France who have developed a widespread infection called borreliosis. This infection is caused by bacteria, often referred to as Lyme disease, and can affect different parts of the body. The research focuses specifically on patients who have received a particular type of modern medicine known as anti-CD20 treatment. These treatments are often used for conditions like certain cancers and diseases where the body's immune system mistakenly attacks its own tissues.
The main aim of this study is to paint a clear picture of these cases. Researchers want to understand everything from the symptoms people experienced, to the results of their blood tests and scans, and details about the anti-CD20 medication they were taking. By collecting all this information, they hope to learn more about how borreliosis affects people who are also undergoing anti-CD20 treatment.
Understanding these cases better is really important. It can help doctors spot these infections sooner, understand how they progress, and decide on the best ways to treat them in the future. The findings could lead to improved care and better outcomes for patients who develop borreliosis while on anti-CD20 therapy.
Key takeaways
- This study is about widespread Borrelia infections (like Lyme disease) in people taking anti-CD20 drugs.
- It aims to describe and understand these specific cases better.
- Participation involves looking at past medical records only.
- There are no physical risks or new demands on patients.
- The findings could lead to better diagnosis and treatment for future patients.
Who may be eligible?
To be part of this study, you would need to be a child or an adult who has been diagnosed with a widespread Borrelia infection (like Lyme disease). This diagnosis must have been confirmed by specific lab tests that look for the Borrelia bacteria in your body.
Crucially, you would also need to have received an anti-CD20 medication within two years before your Borrelia infection was confirmed. The Borrelia infection must have been diagnosed specifically between January 1, 2010, and July 30, 2025.
You cannot participate if you do not wish to be part of the study. This project is specifically looking at past medical records within certain timeframes, so new treatments or ongoing participation are not required.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Have you been diagnosed with a widespread Borrelia infection?
- Was this diagnosis confirmed by lab tests for Borrelia bacteria?
- Did you receive an anti-CD20 medication within 2 years before your Borrelia diagnosis?
- Was your Borrelia infection diagnosed between January 1, 2010, and July 30, 2025?
- Are you happy for your existing medical records to be reviewed?
What does participation involve?
If you are eligible, taking part in this study would mainly involve your medical information being reviewed. Researchers will look at your existing medical records from between January 1, 2010, and July 30, 2025. This includes details about your Borrelia infection, the results of your tests (like blood tests or scans), and information about the anti-CD20 medication you received. You won't need to attend extra hospital visits, take new medicines, or have any additional tests for this study. The study focuses on collecting and analysing information that has already been recorded during your usual medical care.
Potential risks and benefits
Locations (1)
- Laboratoire de Bactériologie - CHU de Strasbourg - FranceVerified postcodeStrasbourg, France· Recruiting
Common questions
What is Borrelia infection?
Borrelia infection is usually known as Lyme disease in the UK. It's caused by bacteria carried by ticks and can affect different parts of the body if not treated.
What are anti-CD20 treatments?
These are specific types of medicines often used for certain immune system conditions or cancers. They work by targeting particular cells in your body.
Will I have to do anything new for this study?
No, if you're eligible, the study will only involve looking at your existing medical records. You won't need new appointments, tests, or medication.
Why is this study important?
It could help doctors understand how Borrelia infections appear in people who are also taking anti-CD20 medication. This knowledge can improve how these conditions are diagnosed and treated in the future.
Is my personal information kept private?
Yes, all your medical information will be kept confidential and handled according to strict privacy rules to protect your identity.
How to find out more
Pierre BOYER, MD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.